More than 40 leading investigators affiliated with US Oncology Research involved in 19 oral presentations, posters, discussions and publications
The Woodlands, Texas (Dec. 3, 2013) - World-class investigators affiliated with US Oncology Research participated in studies that will be presented Dec. 10-14 at the Henry B. Gonzales Convention Center during the 2013 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), an international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer.
Devchand Paul, D.O., Ph.D., F.A.C.P., breast oncologist with Rocky Mountain Cancer Centers, a practice affiliated with The US Oncology Network and US Oncology Research, is lead author of a study titled, Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy. Dr. Paul will present study findings during an oral presentation on Thursday, Dec. 12 from 11:00-11:15 a.m., providing an in-depth look at letrozole plus dasatinib as first-line aromatase inhibitor treatment for hormone receptor positive, metastatic breast cancer, in postmenopausal women. c-Src is a tyrosine kinase involved in breast cancer invasion, proliferation, survival, and is involved in endocrine therapy resistance. Dasatinib is an oral c-Src inhibitor.
"This small, preliminary report is exciting in that it potentially lays the foundation for future studies in preventing or reversing resistance to aromatase inhibitor therapy," said Dr. Paul.
Additionally, more than 40 investigators affiliated with US Oncology Research participated in the studies listed below that will be featured at the conference. For more information or to interview an investigator, contact US Oncology Research Public Relations Manager, Claire Crye at 281-863-6783.
Oral Presentations:
1. Thursday, Dec. 12, 11:00-11:15am, Exhibit Hall D
Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy.
Paul D, Vukelja SJ, Holmes FA, Blum JL, McIntyre KJ, Kumar AR, Lindquist D, Osborne CR, Sanchez-Rivera IJ, Goldschmidt J, Wang Y, Asmar L, Lee M, Wu NCY, Logie K,O'Shaughnessy JA.
2. Wednesday, Dec. 11, 9:15-9:30am, Exhibit Hall D
Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer.
Slamon DJ, Swain SM, Buyse M, Martin M, Geyer CE, Im Y-H, Pienkowski T, Kim S-B, Robert NJ, Steger G, Crown J, Verma S, Eiermann W, Costantino JP, Im S-A, Mamounas EP, Schwartzberg L, Paterson A, Mackey JR, Provencher L, Press MF, Thirlwell M, Bee- Munteanu V, Henschel V, Crepelle-Flechais A, Wolmark N.
Poster Discussion:
3. Thursday, Dec. 12, 5:00-7:00pm, Ballroom A
Comparison of Mutations and Protein Expression in Potentially Actionable Targets in 5500 Triple Negative vs. non-Triple Negative Breast Cancers.
O'Shaughnessy J, Gatalica Z, Kimbrough JM, Millis SZ.
Posters:
4. Wednesday, Dec. 11, 5:00-7:00pm, Exhibit Halls A-B
Clinical impact of internet-based tools to help guide therapeutic decisions for metastatic breast cancer (MBC).
Obholz KL, Blackwell KL, Glück S, Jahanzeb M, Miller KD, Robert NJ, Bowser AD, Mortimer J, Carlson RW.
5. Thursday, Dec. 12, 7:00-9:00am, Exhibit Halls A-B
A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer.
Baselga J, Morales S, Awada A, Blum J, Tan A, Ewertz M, Cortes J, Moy B, Ruddy K, Haddad T, Ciruelos E, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Prathiraja K, Gause C, Mauro D, Rugo H.
6. Thursday, Dec. 12, 7:00-9:00am, Exhibit Halls A-B
Retrospective analysis of long-term survivors with HER2+ metastatic breast cancer (MBC) treated with trastuzumab in a community setting.
Jones S, Tseng W-Y, Saravanan S, Santos E, Dhanda R, Rembert DS, Yap MA, Lalla D, Brammer M.
7. Thursday, Dec. 12, 5:00-7:00pm, Exhibit Halls A-B
Increased risk of second cancers in patients with breast cancer under age 50 years and the identification of non-BRCA inherited cancer syndromes using next generation hereditary cancer panels.
Diab S, Stuenke A, Kagey J, Hamlington B, Keiles S, Freivogel M, Asmar L, Langer L.
8. Thursday, Dec. 12, 5:00-7:00pm; Exhibit Halls A-B
Pattern of Use of an Online Primary Healthcare Information Resource for Breast Cancer Survivorship Education: The Pink Ribbon Survivors Network.
Fisher RE, Jensen L, Adams KA.
9. Thursday, Dec. 12, 5:00-7:00pm, Exhibit Halls A-B
Dose delays, dose reductions, and relative dose intensity in early stage breast cancer patients receiving (neo)adjuvant chemotherapy in community oncology practices.
Favret AM, Li X, Denduluri N, Morrow PK, Bhor M, Barron RL, Dhanda R, Langeberg WJ, Saravanan S, Girardi V, Lyman GH.
10. Thursday, Dec. 12, 5:00-7:00pm, Exhibit Halls A-B
A Phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival.
Awada A, Kaufman PA, Yelle L, Cortes J, Wanders J, O'Shaughnessy J, Olivo MS, He Y, Garzon F, Dutcus CE, Binder TA, Twelves C, Perez EA.
11. Thursday, Dec. 12, 5:00-7:00pm, Exhibit Halls A-B
Eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer: results of a phase 2, multicenter, single-arm study.
McIntyre K, O'Shaughnessy J, Schwartzberg L, Glück S, Berrak E, Song J, Rege J, Cox D, Vahdat L.
12. Thursday, Dec. 12, 5:00-7:00pm, Exhibit Halls A-B
Relative dose intensity of taxane-based chemotherapy in patients with stage IV breast cancer.
Denduluri N, Havrilesky L, Bhor M, Bhowmik D, Morrow PK, Watson H, Dhanda R, Li X, Chung H, Saravanan S, Barron R, Crawford J.
13. Thursday, Dec. 12, 5:00-7:00pm, Exhibit Halls A-B
Buparlisib (BKM120), an oral pan-PI3K inhibitor, in combination with paclitaxel in patients with HER2-negative, inoperable, locally advanced or metastatic breast cancer, with or without PI3K pathway activation: A Phase II, randomized, double-blind, placebo-controlled study (BELLE-4).
Martin M, Batista N, Shtivelband M, Chan A, Delaloge S, Dirix L, Lee SC, Le Mouhaer S, Nanni S, DiTomaso E, Urban P, O'Shaughnessy J.
14. Friday, Dec. 13, 7:30-9:00am, Exhibit Halls A-B
Identification of a Common Genotype in Patients (pts) with HER2-Positive, ER-Negative, Inflammatory Breast Cancer (IBC) that was Primary-Refractory to Trastuzumab Who Have Had 5+ Years of Disease Control with Lapatinib Therapy.
O'Shaughnessy J,Levin M, Palmer G, Ross JS, Palma N, Yelensky R, Cao Y, Ramos C, Hoke G, Wang K.
15. Friday, Dec. 13, 7:30-9:00am, Exhibit Halls A-B
Phase 2, multicenter, single-arm study of eribulin mesylate + trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
Wilks S, Puhalla S, O'Shaughnessy J, Schwartzberg L, Berrak E, Song J, Rege J, Cox D, Vahdat L.
16. Friday, Dec. 13, 5:00-7:00pm, Exhibit Halls A-B
(tnAcity): A phase 2/3 randomized study of weekly nab-paclitaxel in combination with gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer.
Yardley DA, Brufsky A, Conte P, Cortes J, Glück S, Nabholtz J-MA, O'Shaughnessy J, Li L, Barton D, Fandi A, Harbeck N. On behalf of the tnAcity investigators.
17. Friday, Dec. 13, 5:00-7:00pm, Exhibit Halls A-B
A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer.
Traina TA, O'Shaughnessy J, Kelly C, Schwartzberg L, Gucalp A, Peterson A, Bhattacharya S, Trudeau M, Hudis CA, Schmid P.
18. Saturday, Dec. 14, 7:30-9:00am, Exhibit Halls A-B
Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US Oncology trial 01062.
O'Shaughnessy J, Koeppen H, Crockett M, Lackner M, Spoerke JM, Wilson T, Levin MK, Pippen J, Paul D, Stokoe C, Blum J, Holmes FA, Lindquist DL, Krekow L, Vukelja SJ, Sedlacek S, Rivera R, Brooks RJ, McIntyre KJ, Schwartz JE, Jones S.
Publication:
19. Treatment Patterns in Patients With HER2-Positive Metastatic Breast Cancer.
Tripathy D, Cobleigh M, Hurvitz S, Jahanzeb M, Kaufman P, Mason G, Mayer M, O'Shaughnessy J, Rugo H, Yoo B, Beattie M, Yardley D.
Numerous clinical studies led by US Oncology Research affiliated physicians have been prominently featured at conferences held around the world, including the American Society of Clinical Oncology (ASCO) Annual Meeting, the American Society of Hematology (ASH) Annual Meeting and Exposition, and the European Society for Medical Oncology (ESMO) European Cancer Congress. From January to October 2013, more than 100 independent registration and investigator-initiated studies were published in peer reviewed journals by investigators associated with US Oncology Research and/or The US Oncology Network. These studies featured forward looking clinical research topics that are helping advance cancer care today and discover improved therapies for the cancer care of tomorrow.
About US Oncology Research
Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 80 research sites and 225 locations managing about 225 active trials at any given time. Physicians in the research network have enrolled more than 56,000 patients in nearly 1,300 trials since inception in 1992 and have contributed to the development of 47 cancer therapies approved by the FDA. For more information call (800) 482-6700 or visit www.usoncology.com/oncologists.
PR Contact
Contact Public Relations